Are you Dr. Garraway?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 95 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
# D1542
Boston, MA 02115Phone+1 617-632-6689
Summary
- Dr. Levi Garraway, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2005
Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2001
Harvard Medical SchoolClass of 1999
Certifications & Licensure
MA State Medical License 2001 - 2018
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2009
Clinical Trials
- Whole-Exome Sequencing (WES) of Cancer Patients Start of enrollment: 2012 Sep 01
Publications & Presentations
PubMed
- A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer.Veronica Rendo, Michael Schubert, Nicholas Khuu, Maria F Suarez Peredo Rodriguez, Declan Whyte
Nature Communications. 2025-01-27 - A standing platform for cancer drug development using ctDNA-based evidence of recurrence.Arielle J Medford, Ariel B Carmeli, Alexandra Ritchie, Nikhil Wagle, Levi Garraway
Nature Reviews. Cancer. 2024-11-01 - 28 citationsAn activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.Abhinav Jaiswal, Akanksha Verma, Ruth Dannenfelser, Marit Melssen, Itay Tirosh
Cancer Cell. 2022-05-09
Press Mentions
Lupus Nephritis Drug Delivers Promising Results, Says RocheFebruary 7th, 2025- New England Journal of Medicine Publishes New Data for Roche’s Gazyva/Gazyvaro Which Shows Superiority over Standard Therapy in People with Active Lupus NephritisFebruary 6th, 2025
- FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related BlindnessFebruary 4th, 2025
- Join now to see all
Grant Support
- The Use Of Whole-Exome Sequencing To Guide The Care Of Cancer PatientsNational Human Genome Research Institute2012
- High-Throughput Tumor Genomic Profiling By Massively Parallel SequencingNational Cancer Institute2011
- High-Throughput Oncogene Mutation Detection In Human CancerNational Cancer Institute2010–2011
- Integrated Functional Genomic Analyses Of MelanomaNational Cancer Institute2005–2009
- Functional Analysis Of The PTEN Tumor Suppressor ProteinNational Cancer Institute2005–2009
- High-Throughput Oncogene Mutation Detection In Human CancerNational Cancer Institute2007–2008
- Defining Melanoma Therapeutic Avenues By Integrative Functional GenomicsOffice Of The Director, National Institutes Of Health2007
- Molecular Genetics Of Parasite VirulenceNational Human Genome Research Institute1992–1998
Professional Memberships
- Member
